Results 141 to 150 of about 802,581 (339)
Effect and Threshold of Endoscopic Findings for CRS Control Status and Long‐Term Outcome Prediction
ABSTRACT Background EPOS 2020 defined chronic rhinosinusitis (CRS) disease control using patient symptoms and medication usage but endoscopic findings were considered optional. The effect of adding endoscopic features, an appropriate threshold, and their association with present or future symptom control have not been studied.
Steven Chun‐Kang Liao +14 more
wiley +1 more source
Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
American Journal of Hematology, EarlyView.
Rong Wang +9 more
wiley +1 more source
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol +14 more
wiley +1 more source
Medical service fees – a key step forward
Wei-Ping Jiao, Qiang Shi
doaj +1 more source
Prevalence of eye and adnexal disorders among elderly inmates in Taiwan prisons
Background Prisoner health is a topic of significant importance; however, it has received limited attention in epidemiological studies, likely because of challenges in obtaining relevant data.
Ching-Yao Tsai +6 more
doaj +1 more source
ABSTRACT Background Appropriate medical therapy (AMT) is first‐line treatment for patients with chronic rhinosinusitis (CRS). We evaluated inflammatory structure, treatment‐induced changes, and biomarker‐outcome associations in AMT‐managed patients. Methods Fifty‐one CRS patients were evaluated before and after AMT which included a combination of oral ...
Asher C. Park +9 more
wiley +1 more source
Key Points Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.
Eric R. Ramos +7 more
wiley +1 more source
Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis
ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman +9 more
wiley +1 more source

